Siltuximab: A Deep Dive into CNTO-328 and Its Clinical Applications CNTO-328 represents a novel monoclonal agent targeting interleukin-6 subunit, offering a targeted approach to managing various inflammatory disorders. Initially researched as CNTO-328, this medication has demonstrated efficacy in refractory angiosarcoma , particularly those resis